Q1. Is there a requirement to visit the sites of the demonstration project?
A1. There is no requirement to visit the trial sites for this review.
Q2. Can all consultations be conducted via video/audio?
A2. The methodology for consultation is at the discretion of the applicant and should be detailed in the application.
Q3. What is the nature of the economic analysis of the trial data that has been undertaken for each project by the project teams?
A3. The economic analysis has been varied and will differ according to each project. Details of the economic analysis will be provided to the successful applicant, however existing data from a range of sources includes: crop production data, ex ante benefit cost analysis and assumptions, yield gap data and qualitative grower practices data, transect survey data in some locations, and qualitative behaviour change data.
Q4. What control data is available for any baseline comparison of the trial data?
A4. This will vary project to project on what baseline data is available. Data relevant to a ‘control’ will be specific to the methodology proposed by the applicant and as such is difficult to answer. This will be discussed with the preferred applicant in the negotiation phase.
Q5. How many GRDC investment managers, and project partners including the National Pulse Adaptability project (NAPA) team members need to be interviewed?
A5. There are five GRDC investment managers and five D&E project partners (WA,SA, Vic and NSW) and the CSIRO NaPA team to be interviewed.
Q6. Note that the title of the Review is "A review of GRDC’s historic and current grain legume D&E investment”, however in the supporting text, notably under ’Summary’ and ‘Outputs'' it appears to have a focus only on four current investments that are listed.
Is this review to only include the four investments listed, or is it to include previous (historic) investments as well? If historic investments are to be included, will GRDC identify these, so applicants are clear on exactly how many investments are to be included in the review.
A6. The review will focus on the four current investments, however, if the proposed methodology requires data from previous investments, GRDC will provide this in negotiation with the successful applicant.
Q7. Assuming only the four investments listed in the Request of Tender are to be reviewed, what documents will GRDC be providing to the review? It is expected that various reports from the investments, including Annual Progress Reports, Final Technical Reports, supporting extension and communication material, details of contracted Outcome and Outputs. Can GRDC confirm what documents will be provided to the Review?
A7. All reports generated as part of the four current projects, along with internal economic analysis and any previous review material will be provided to the successful applicant.
Q8. A review would seek to take input from the relevant investment leaders, the appropriate GRDC investment managers and other involved stakeholders or consultants/agronomists. To what degree will GRDC assist with identifying key people to be interviewed and help with contact details / setting up meetings and similar?
A8. GRDC is happy to provide contact details of key stakeholders to the successful applicant but will not be responsible for setting up meetings.
Q9. Does GRDC have any supporting data on adoption of the Outcomes from these investments, for example areas of the various grain legume crops since the investments were initiated, any survey data about grower adoption, attitudes or similar about grain legume growing? If so, will this data be made available to the review?
A9. This will vary project to project on what baseline data is available. Data relevant to a ‘control’ will be specific to the methodology proposed by the applicant and as such is difficult to answer. This will be discussed with the preferred applicant in the negotiation phase.
Q10. Can I please confirm that the sites of interest for this review are as described in article [Fit for purpose research targets pulse profitability - GroundCover] Linked?
A10. The article referenced does correctly highlight the investments in each region. There are many trial sites within each region, trialling a range of different treatments.